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Abstract
Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1
vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in
eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease
progression. Autologous nAb titers at study exit were significantly higher compared to
contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb IC50 titers correlated
inversely with V1-V2 length (p=0.04). Significant differences in breadth and potencies were noted
against subtype C compared to subtype A (p= 0.03 and p=0.01) or subtype B (p= 0.03; p=0.05)
viruses respectively. IgG binding affinity for gp41 was higher than for gp120 (p=0.0002). IgG-
FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb
(p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune
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function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1
disease progression.
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Introduction
In 2010 alone, there were an estimated 2.4 to 2.9 million new HIV-1 infections worldwide
with 70% of these new infections occurring in sub-Saharan Africa (UNAIDS, 2011). This
high HIV incidence makes the development of a protective vaccine a global public health
priority. Such a vaccine will likely need to elicit antiviral antibodies, similar to the
successful vaccines against other viral infections such as hepatitis B, measles, mumps and
polio that are thought to mediate their effects primarily through antibody mechanisms
(Plotkin, 2008). However, despite intense efforts in the study of HIV envelope structure and
immunogen design, the development of an efficacious vaccine able to induce broadly
effective antibody responses remains elusive.
During natural HIV infection, only a subset of individuals, less than 30%, develop broad,
cross-neutralizing antibodies after many years (Gray et al., 2011; Li et al., 2009; Sather et
al., 2009; Simek et al., 2009; Stamatatos et al., 2009). Such individuals have been an
important source of new neutralizing monoclonal antibodies (nmAbs) against the HIV
envelope that have enhanced our understanding of HIV pathogenesis, envelope structure and
provided clues for rational immunogen design (Pejchal et al., 2011; Walker et al., 2010; Wu
et al., 2010). However, clinical benefit of anti-HIV antibodies has not yet been definitively
demonstrated. Given that HIV-1C is the predominant circulating and most rapidly spreading
subtype worldwide (Esparza, 2005; Hemelaar et al., 2011), screening, characterizing and
understanding the types of nAbs produced by HIV-1C-infected individuals; and defining the
potencies and breadth of these nAbs may contribute to the design of the next generation of
envelope immunogens.
While only some people develop cross-neutralizing antibodies, autologous nAbs (AnAbs)
appear in almost all HIV-infected individuals usually within the first year. A number of
studies have shown that contemporaneous viruses are less sensitive to AnAbs than earlier
autologous viruses suggesting that viral evolution and escape occurs rapidly and this
remains a significant obstacle to HIV vaccine development (Delwart et al., 1997; Moore et
al., 2009; Richman et al., 2003; Rong et al., 2009; Wei et al., 2003). Several mechanisms of
viral escape have been documented; these include insertions and deletions of amino acids,
amino acid substitutions and shifting the position of N-linked glycans in Env (Frost et al.,
2005; Lynch et al., 2011; Moore et al., 2009; Rong et al., 2009). Further understanding of
HIV antibody escape patterns and mechanisms may help to inform better immunogen design
to overcome Env diversity and immune escape.
Although the major focus of the HIV vaccine field is the development of immunogens able
to induce broadly neutralizing antibodies, V1-V2 binding antibodies appear to have played
some role against HIV-1 acquisition in the RV144 vaccine trial (Haynes et al., 2012). The
role of binding or non-neutralizing antibodies in inhibiting virus replication through an Fc
(fragment crystallizable) receptor (FcR)-dependent mechanism has been demonstrated
(Peressin et al., 2011). FcRs are part of the immunoglobulin (Ig) superfamily and bind to the
Fc portion of antibodies forming a bridge between the cell bearing the target antigens and
the effector cell (Nimmerjahn and Ravetch, 2007). FcγRs have either an activating or
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inhibitory function with relative IgG binding affinities. FcγRI (high affinity), FcγRlla and
FcγRllla (medium-low affinity) - all have activating functions; and FcγRllb has an
inhibitory function (medium-low affinity) (Forthal and Moog, 2009; Siberil et al., 2007).
The effector cell subsequently mediates virus killing through antibody-dependent cell
mediated cytotoxicity (ADCC) or through antibody-dependent cell-mediated viral inhibition
(ADCVI). Some studies have shown that the strength of binding interaction between the Fc
region of the antibody and the FcγRIlla and/or FcγRlla potently increases ADCC activity
and Fc binding affinity could be altered through deglycosylation or site-specific
mutagenesis, abrogating downstream ADCC (Jefferis, 2009; Lazar et al., 2006; Richards et
al., 2008; Shields et al., 2001). Thus Fc-binding interaction may be crucial to improving the
efficacy of antibodies (Lazar et al., 2006). These studies therefore provide a rationale for
assessing the binding affinities of the IgG-Fc regions to their cognate FcγRs as an indication
of putative antiviral activity of binding antibodies in vivo. Previously, ADCC activity was
reported to be significantly higher in elite controllers compared to chronic progressors
(Lambotte et al., 2009). These data on HIV are consistent with earlier studies suggesting a
role for non-neutralizing antibodies in viral control and disease attenuation (Alsmadi et al.,
1997; Baum et al., 1996). More recently, it was demonstrated that non-neutralizing
antibodies conferred protection, albeit limited, to macaques against vaginal SHIV challenge
(Burton et al., 2011). The binding affinities of IgGs to various HIV-1 antigens and to FcγRs
have rarely been studied together and no studies have reported on the characterization of
these antibodies in chronic HIV-1 subtype C infections.
In this study, we used standard high throughput neutralization assays to evaluate the potency
and breadth of neutralizing activity in patient plasma and map potential Env targets
associated with nAb breadth. We profiled autologous and cross-reactive (against a standard
panel of 20 subtype A, B and C viruses) nAb titers in eight chronically HIV-1C infected
individuals with heterogeneous rates of disease progression. Envelope genotypic
characteristics (amino acid length and numbers of potential N-linked glycosylation sites
(PNGs) associated with autologous nAb titers were investigated. Binding affinities of total
immunoglobulins (IgGs) to HIV-1 antigens (gp41, gp120 and p24) and FcγRs (FcγRI,
FcγRlla, FcγRllb and FcγRIIIa) were quantified. Associations between autologous nAb




Participant samples were retrospectively identified from the Sinikithemba cohort, which is a
prospective natural history study of HIV-1 infected individuals based at McCord Hospital,
Durban, South Africa as previously reported (Kiepiela et al., 2004). Human subjects for this
study were eight chronically-infected individuals with heterogenous rates of clinical disease
progression as previously described (Archary et al, 2010). The median period of follow-up
overall was 21 months. Ethical approval for this study was obtained from the University of
KwaZulu-Natal Biomedical Research Ethics Committee and all participants gave written
informed consent to participate in the study.
Sample Collection, CD4 T-cell counts and Plasma Viral Load
CD4 T-cell counts were performed at three-month intervals whereas viral loads were done at
six-month intervals as previously described (Archary et al., 2010). Blood was drawn from
each subject into EDTA tubes and plasma was separated by centrifugation and stored at
−80°C until use. Viral load was measured using the Amplicor Version 1.5 assay (Roche,
Archary et al. Page 3










Alameda CA, USA). CD4 T-cell counts were enumerated by Trucount technology on a four
colour FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, New Jersey, USA).
Envelope clones
Briefly, single genome PCR amplification derived env amplicons were directionally T/A
cloned into the CMV-driven expression plasmid pcDNA3.1-V5 HisTOPO-TA and screened
for biological function as pseudoviruses following co-transfection with an env-deficient
subtype B proviral plasmid (SG3ΔEnv) into 293T cells as described previously (Derdeyn et
al., 2004; Haaland et al., 2009). A total of 20 standard reference envelope clones were
obtained from the NIH AIDS Research and Reference Reagent Program and used in the
heterologous neutralization assays. These included five subtype A, seven subtype B and
eight subtype C envelope pseudoviruses as depicted in Table 2. Tier 1, 2 and 3 viruses were
stratified previously based on a continuum of patterns of neutralization sensitivity- with tier
1A being the most sensitive, tier 1B above average, tier 2 displaying moderate to low
sensitivity and tier 3 displaying the lowest sensitivity to neutralization (Seaman et al., 2010).
The ConC plasmid based on the consensus of all the HIV-1 subtype C sequences from the
Los Alamos database by 2001 was obtained from Dr Feng Gao (Kothe et al., 2006). The
envelope plasmids containing single point mutations are described in Gray et al (2011).
Neutralization assays
Patient plasma samples were evaluated for nAb activity against virions pseudotyped with
autologous patient-derived viral Envs using a single reporter assay as described previously
(Derdeyn et al., 2004; Gray et al., 2007; Li et al., 2005; Li et al., 2006; Wei et al., 2003).
Figure 1A illustrates the schema used for autologous neutralizing antibody challenge assays
where the study entry and exits Envs were tested for neutralization using the study entry and
study exit plasma nAb samples for eight study participants. A total of 37 autologous Envs
were tested against their study entry plasma and study exit plasma (range: 2-6 env clones per
participant). Neutralization was measured as a reduction in luciferase gene expression after a
single round of infection of TZM-bl cells (NIH AIDS Research and Reference Reagent
Program). Two thousand infectious units of each pseudovirus was combined with five-fold
dilutions of heat-inactivated participant plasma and incubated for 1 hour at 37°C as
previously described (Rong et al., 2009). Subsequently, the virus and antibody reaction was
added to the plated TZM-bl cells, and left to incubate at 37°C for 48 hours. The cells were
then lysed and the luciferase activity was determined using a BioTek Synergy HT (BioTek,
USA). The background luminescence of the uninfected wells was subtracted from the test
wells. The percentage of infectivity was calculated by dividing the number of luciferase
units at each plasma dilution by the value in the well containing no test plasma. The dilution
that yielded 50% inhibitory activity against the virus, known as the nAb IC50 titer was
determined on Microsoft Excel. Each experiment was performed in duplicate and
independently at least twice for replicability. The nAb IC50 titer was calculated as the
reciprocal plasma dilution causing a 50% reduction of relative light units (IC50).
Heterologous assays were done as previously reported (Montefiori, 2004). Briefly, positive
neutralization was scored as an IC50 titer above 1:45. The nAb breadth and potency was
determined as a score based on the median IC50 titer for each virus as reported in Blish et al.
(2008).
Plasma IgG Isolation
Total IgGs were purified from the participant's plasma samples using the Melon Gel
(Thermo Scientific, Surrey, United Kingdom) method according to the manufacturer's
instructions. Briefly, 500 μl of a 1:10 dilution of plasma to buffer was added to the column.
The tubes were rotated for 5 minutes in order to ensure maximum capture of the IgGs and
were then spun down for 1 minute at 5,000 × g to elute the IgGs. IgG concentrations were
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measured on the NanoDrop 2000 Spectrophotometer (Thermo Scientific, Surrey, United
Kingdom) and stored at 4°C for downstream ELISA assays.
FcGamma (γ) Receptor Binding ELISAs
Binding affinities of the bulk population of IgGs purified from plasma were measured for
the various activating- FcγRI, FcγRIIa and FcγRIIIa- (R&D Systems, Minneapolis, USA)
and inhibitory receptors - FcγRIIb.
Each ELISA plate (Ni-NTA HisSorb™ Plate Qiagen, Dusseldorf, Germany) was coated
with 100 μl/well of diluted FcγR (FcγRI, FcγRIIa, FcγRIIb, and FcγRIIIa) at a
concentration of 5 μg/ml using PBS. One receptor type per plate was added and incubated
overnight (O/N) at room temperature (RT). The plate was washed three times with PBS-
Tween (0.05%) and blocked with 250 μl/well 5% PBS-Bovine Serum Albumin (BSA)
(Sigma-Aldrich, St Louis, USA) and then incubated for 1 hour at RT. The plate was washed
three times with 0.05% PBS-Tween. 100 μl/well of antibodies were added (the IgGs derived
from the test plasma were diluted serially starting at 100 μg/μl diluted down to 1.6 μg/μl) to
the respective wells and was left to incubate for 1 hour at RT. The plate was washed three
times with 0.05% PBS-Tween. 100 μl per well of anti-human IgG antibody, Fab fragment,
peroxidase labeled was added (KPL Protein Research Products, Maryland, USA). 20 μl of
HRP Fab (1 mg/ml) was added to 10 mls PBS 1× for one plate. The plate was incubated for
1 hour at RT and covered to protect it from light. The plate was washed three times with
0.05% PBS-Tween. The colour was resolved with 100 μl/well of O-phenylenediamine
(OPD) (Sigma-Aldrich, St Louis, USA) - one OPD tablet was added to 11 mls of StrepHRP
substrate), the reactions were stopped by adding 100 μl/well of 2.5N sulphuric acid (Sigma-
Aldrich, St Louis, USA). The plate was read at 490 nm using the Tecan Sunrise 16039400
plate reader (Tecan Group, Switzerland). The optical density data was exported to Microsoft
Excel worksheet to calculate the 50% effective concentration (EC50) of each batch of total
IgGs needed to bind HIV-specific gp41, gp120 and p24 antibodies and various FcγR using
an ELISA-based assay. EC50 (μg/ml) corresponds to the concentration of antibody needed
to achieve half of the maximal binding to FcγR. The EC50 binding titer of the IgGs was
used as a surrogate indicator of how strongly or poorly the IgGs' Fc portion may bind to the
FcγR to recruit effector cells like phagocytic (macrophages) or non-phagocytic (natural
killer cells) cells to initiate either ADCVI or ADCC activity. Essentially, the higher the EC50
the more antibody is needed for antiviral activity like ADCC or ADCVI to occur, the lower
the affinity of antibody binding to the respective target cells bearing the antigens e.g. the
FcγRs to antibodies to initiate effector functions.
Gp120, gp41, and p24 Binding ELISAs
Binding affinities of the bulk population of IgGs purified from plasma were measured for
the various HIV-1 specific antigens- gp120, gp41 and p24. ELISA plates were coated with
80 μl/well of 250ng/ml gp120 (Immune Technology, New Jersey, USA) or gp41 (Immune
Technology, New Jersey, USA) or p24 (Immune Technology, New Jersey, USA) and then
incubated O/N at 4°C. The plates were washed three times with PBS Tween 0.05% and
blocked with 5% PBS-BSA for 2 hours at RT (100 μl/well). IgGs isolated previously were
diluted in PBS and added to respective wells according to a ten times serial dilution to
respective wells and incubated for 2 hours at RT. The plates were washed three times with
0.05% PBS Tween. 100 μl anti-human IgG antibody, Fab fragment, peroxidase labeled was
added to each well (KPL Protein Research Products, Maryland, USA) and left for 1 hour at
RT (1:500 diluted-per plate: 20 μl HRP in 10 ml PBS) and covered in tinfoil. The plate was
washed 3 times with 0.05% PBS-Tween. One OPD tablet was added to 11 mls of phosphate
citrate buffer + 4.4 μl Hydrogen Peroxide (H2O2); and 50 μl/well were added. The reaction
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was stopped by adding 50 μl 2.5 N H2SO4 per well. The plate was read at 490 nm on a
microplate reader and the data analyzed using GraphPad Prism 5 software.
Statistical analyses
Comparisons of different parameters including nAb IC50 titers for both the autologous and
heterologous responses, and binding affinities of the various HIV-specific antigens and
FcγRs to IgGs was performed. Intra-group comparisons between study entry and study exit
time-points were done using the Mann-Whitney U test and the Spearman rank correlation
test. ANOVA was used to compare three or more groups and the Dunn's post-test was used
to perform pairwise comparisons. A general linear model was used to estimate the rate of
change in viral load and CD4 T-cell count over time. Viral load was log-transformed to
ensure normality. All reported p values are two-sided and are considered significant if less
than 0.05. The statistical analysis was performed using GraphPad Prism 5 and SAS version
9.3 (SAS Institute Inc., Cary).
Results
Study Participants
There were eight participants in this study, seven female and one male. Table 1 depicts the
clinical profiles of the participants for this retrospective study. All participants were of
African descent. All participants were antiretroviral treatment naïve for a median of 21
months. The median age was 31 years (range: 22-59 years). The median CD4 T-cell count at
study entry was 578 cells/μl (range: 503-936 cells/μl) and at study exit was 369 cells/μl
(range: 218-881 cells/μl). The median viral load at study entry was 6,140 copies/ml (range:
2,210-14,360 copies/ml) and at study exit was 14,750 (range: 2,440-345,000 copies/ml). The
mean CD4 T-cell decline rate was −7 cells/μl per month (standard error 1.50 cells/μl). Since
data on the length of time that participants were infected was unavailable, sequence analysis
was performed by using the Bayesian evolutionary analysis by sampling trees (BEAST) to
estimate the approximate time of infection in both groups of participants. Participants were
estimated to be infected for a mean period of 5.1 years (range: 9 months-15 years).
Autologous Neutralizing Antibody Responses become potent over time in chronic
infection
To better understand autologous neutralization during chronic infection we tested the
participants' plasma against their plasma-derived Envs using a pseudovirus-based assay (see
Figure 1A). The titers represented on Figure 1B were the average nAbIC50 titers of two or
three Envs per participant.
NAb IC50 titers for the study entry and study exit Envs differed when the study entry and
study exit plasma antibody responses were compared. As shown in Figure 1B, there were
significant differences when the study entry Envs were tested against the study exit plasma
(median nAb IC50 of 1,178; range: 610-2,286) compared to the contemporaneous responses
at study entry (median nAb IC50 of 429; range: 119-628; p=0.002) and study exit (median
nAb IC50 of 305; range: 210-1,076; p=0.01). There were no correlations between the rates of
CD4 T-cell decline or viral loads with for the nAb IC50 titers of study entry Envs against the
study exit plasma or between contemporaneous nAb IC50 titers at study entry or study exit-
Figure 1C and1D.
Autologous neutralization titers correlated with the length of the hypervariable regions V1-
V2
Previous studies have shown an inverse association between neutralizing antibody titers and
length of variable loops (V1-V2) and numbers of potential N-linked glycosylation sites
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(PNGs) (Chackerian et al., 1997; Gray et al., 2007; Pinter et al., 2004; Rong et al., 2007;
Sagar et al., 2006). To better understand the relationship between genotypic characteristics
and neutralization sensitivity, the average amino acid length of the hypervariable loops of
Env and PNGs were correlated to average autologous nAb IC50 titers (Figure 2). Significant
inverse correlation was found between the lengths of V1-V2 and nAb IC50 titers (r=−0.80;
p=0.02) for the entry viruses tested against the study exit plasma. There was a trend towards
C2-V5 length correlation with nAb IC50 titers (r=−0.67; p=0.08) and no significant
correlations for V1-V5 (r=0.52; p=0.2). The same analysis was extended for nAb IC50 titers
and the numbers of potential N-linked glycosylation sites (PNGs) in the various
hypervariable loops and there were no significant correlations observed.
Neutralization breadth scores and potency scores indicate subtype-specific responses in
chronic infection
To assess neutralization breadth in this chronic infection cohort, we investigated changes in
plasma neutralization activity over a median of 21 months. Figure 3 depicts the profile of
plasma neutralizing activity against a panel of heterologous Envs for the eight study
participants at study entry and study exit. A total of 20 reference pseudoviruses from
subtype A, B and C (as depicted in Table 2) were used to determine breadth and potency
scores of neutralization according to the criteria previously described (Blish et al., 2008).
Results are presented as a breadth score per subtype virus panel, and a total breadth score
including all the subtype A, B and C viruses. Results are presented as potency scores per
subtype, and total potency scores including all the subtype A, B and C viruses.
There was a wide range of variation in neutralization titers with most of the sera from the
participants displaying preferential heterologous activity against the subtype C panel (Figure
3). Significantly higher breadth scores were observed against subtype C viruses (median: 3;
range: 1-7) compared to subtypes A (median: 2; range: 0-4; p= 0.03) or B (median: 2; range:
0-6; p=0.01) - Figure 3. Likewise, significantly higher potency scores were observed against
subtype C viruses (median: 7.6; range: 0-152.1) compared to subtypes A (median: 4; range:
0-13.8; p= 0.03) or B (median: 3.9; range: 0-26.9; p=0.05). Three of the participants
(SK200, SK221 and SK233) showed a consistent increase of neutralization breadth scores
and potency scores from study entry to study exit for subtypes C, B and A respectively
translating into overall increase in total breadth and potency scores as well. Analysis of these
participants indicated significantly higher viral load at study entry compared to study exit
(p=0.04); suggesting that increasing breadth may be a result of higher antigenic stimulation.
SK200 displayed the highest breadth scores and also had potent nAb IC50 scores (Figure 3)
to six of the eight subtype C viruses tested including five of six tier 2 viruses. SK200 had a
total neutralization breadth score of 16 (range: 2-16) and the overall potency score was
177.1 (range: 3-177.1) at study exit. SK200 neutralized Subtype C- tier 2 viruses -
CAP45.G3 and CAP239.G3 at study entry and exit plasmas, and CAP45.G3 in particular,
was neutralized at nAb IC50 titers of >2,000 (range: 45-5,326). SK200 also displayed the
highest titers >1,000 at study entry (range: 45-1,316) and study exit (range: 45-1,829) to a
subtype A tier 1 virus- Q23ENV17.
CD4 T-cell count and viral load are not correlated with neutralization breadth
A number of studies have shown an inverse relationship between neutralization breadth and
CD4 T-cell counts and a positive correlation with viral loads (Euler et al., 2010; Gray et al.,
2011; Piantadosi et al., 2009; Sather et al., 2009). To better understand the relationship
between neutralization and clinical disease markers in this subtype C chronic cohort, we
investigated the association of CD4 T-cell counts and viral loads with neutralization breadth
or potency over a median of 21 months. However, there were no significant correlations
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between CD4 T-cell counts or viral loads and total breadth and potency scores (data not
shown). A larger sample size may have been able to detect significant correlations between
breadth or potency and markers of disease progression.
Mapping of potential epitopes targeted by cross-neutralizing antibodies
The putative targets of neutralization in participants displaying the highest breadth scores for
neutralization at study exit (SK200, SK221 and SK233) against the reference panel viruses
were further investigated (using study exit plasma samples). Single point mutations in V2
(N160A, K165E or L165A) and C3 (N332A) were introduced into CAP45.G3, ConC,
Du156.12, TRO.11 and Q23.17 and tested for loss of sensitivity against the three plasmas.
As depicted in Table 3, 5.6-fold and 4-fold drops in neutralization titers (relative to the wild
type neutralization titers) were seen when plasma samples from SK221 and SK233,
respectively, were tested against the K169E mutation in the CAP45 backbone. This
suggested that the broadly neutralizing antibodies in these two participants targeted the V2
region and that a charge change from a lysine (K) to glutamic acid (E) at position 169
resulted in a disruption to the nAb epitope. In addition SK221 plasma also showed a 4.2 fold
drop in neutralization titers to N332A made in the TRO.11 envelope indicating that the
asparagine (N), or perhaps a potential N-linked glycosylation at this position, was essential
for the antibody activity. Together, these results suggested that SK221 most likely had cross-
neutralizing antibodies that target the V2 and C3 regions on Env. SK200, who displayed the
highest neutralization breadth score, neutralized the wild-type and mutant viruses
equivalently suggesting that this particular participant may have antibodies directed to other
regions of Env, a profile that warrants further investigation.
HIV-specific IgG binding titers for gp41, gp120 or p24 in chronic infection over 21 months
We isolated total immunoglobulins (IgGs) from study participants at study entry and study
exit time points and measured the specificity and the binding affinity of IgGs to HIV-1
specific antigens. There were no significant differences in the median EC50 binding
affinities between study entry and study exit for gp41, gp120 or p24. Interestingly, at study
entry, the median IgG binding affinities for gp120 (median: 137; range: 11.3-153.0) was
significantly lower than for gp41 (median: 96.8; range: 71.9-112.1; p=0.0002). Binding
affinity for gp120 compared to p24 trended to be higher (median: 154.3; range: 57.9-293.9;
p=0.09)- Figure 4. These findings may suggest that binding IgGs were selectively binding
gp41compared to gp120 during the chronic infection stage. In addition, there were no
significant correlations between the CD4 T-cell counts or viral loads at study entry or exit
with the EC50 of p24, gp120 or gp41 over the study period.
IgG binding affinities differ for the various FcγR I, IIa, IIb and IIIa
To determine if the binding affinities of the IgGs with various activating and inhibitory
FcγRs were different, we measured and compared the EC50 binding titers over time
between study entry and study exit time-points, and overall (Figure 5A). IgG binding for
FcγRI at study entry was significantly higher than for FcγRIIIa (p<0.0005). Likewise at
study exit, the binding affinity of IgG for the FcγRI were consistently higher compared with
FcγRIIb (p<0.05) and FcγRIIIa (p<0.0005). Significantly higher binding affinities for
FcγRIIa at study entry were noted when compared to FcγRIIIa at study entry (p<0.05).
Likewise at study exit, the binding affinity of IgG for the FcγRIIa was higher compared to
FcγRIIIa (p<0.05) in chronic HIV-1 C disease. Collectively, these results indicated that
there was differential kinetics of binding affinities of the IgG during chronic infection,
which may then impact downstream non-neutralizing activity through ADCC. Sustained
high affinity IgG binding to FcγRI may be preserved during chronic infection. There were
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no significant correlations between viral loads or CD4 T-cell counts with the EC50 IgG
binding titers to the various receptors (FcγR I, IIa, IIb and IIIa)- Figures 5B and 5C.
Discussion
Neutralizing and binding antibodies may play a role in HIV disease progression but these
parameters have rarely been investigated concurrently. We therefore undertook this study in
individuals chronically infected with HIV-1 subtype C, the most abundant subtype
worldwide, to characterize neutralizing and binding antibody patterns in chronic disease, and
to determine whether certain genotypic env characteristics are associated with autologous or
heterologous nAb responses. Our data indicated that nAbs did not appear to protect against
disease progression, rather, greater type-specific neutralization breadth and potency against
subtype C Envs and increasing autologous nAb titers were associated with chronic disease
progression. NAb IC50 titers were correlated with env genotypic characteristics, including
increased amino acid length in hypervariable regions V1-V2 of gp120.
In this study, nAb potency or breadth did not predict disease progression rate in individuals
with chronic HIV-1 subtype C infection. However, a number of interesting findings were
apparent. Firstly, high-level neutralizing titers to contemporaneous autologous virus were
not observed in most of the participants. Instead, we observed significantly higher
autologous responses over time (when the study entry viruses were tested against the study
exit plasma) compared to contemporaneous responses, which suggests that nAb are
continuously evolving during chronic infection. These findings also argue that an increased
nAb titer per se is not effective at attenuating disease progression but rather is a marker of
disease progression. Secondly, autologous nAb IC50 titers correlated inversely with longer
amino acid length for V1-V2 length indicating that increased length in this domain may be
masking key neutralization epitopes. Indeed, evidence for V2 dependent epitopes was
observed in SK221 and SK233. This data suggests that V1-V2 of Env may be persistently
targeted by nAb in the chronic infection stage. Alternatively, there may be other intrinsic
genetic differences of env that dictate neutralization potency and breadth that need to be
further defined. Lastly, the dynamic nature of IgG binding affinity to various FcγRs and the
selective high affinity binding to HIV-1 gp41 may be indicative of chronic disease
progression.
The selective increase in neutralization breadth over time suggests that this parameter could
be a marker of disease progression in chronic subtype C infection (Euler et al., 2010).
Neutralization breadth did not significantly correlate with markers of disease progression
(viral loads and CD4 T-cell counts in this chronic HIV-1C infection cohort, although the
small sample size and short time-frame may have severely limited our statistical power to
address this issue. Gray and colleagues (2011) found significant correlations between CD4
T-cell count and viral load with neutralization breadth at six months post-infection only and
not at later time points (Gray et al., 2011). These observations suggest that higher antigenic
stimulation may dictate the breadth of heterologous antibody responses (Doria-Rose et al.,
2010; Fraser et al., 2007; Goujard et al., 2006; Mellors et al., 1997; Piantadosi et al., 2009;
Sather et al., 2009). Although increased neutralization antibody breadth may not be
protective against disease progression, they may be effective against super-infection as has
been suggested by some studies (Smith et al, 2006 and Deeks et al, 2006), although
conflicting data exists (Blish et al., 2008). Together, these studies have implications for HIV
vaccine design, as vaccine immunogens may need to be given over long periods of time to
stimulate the B cell response, and to facilitate affinity maturation which appears to be
necessary for antibodies to acquire cross-neutralizing activity (Pancera et al., 2010; Scheid
et al., 2009). For the participants who displayed potent cross-neutralizing antibody
responses, their nAbs likely targeted quaternary V2 epitopes similar to PG9/PG16-like
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antibodies (Moore et al., 2011). In addition, nAbs that targeted the N332 glycan in C3
suggest that the asparagine in that position is essential for neutralization activity. In subtype
C infection, the V1-V2 and C3 regions are the immunodominant regions commonly targeted
by AnAbs particularly during the early stage of infection (Lynch et al., 2011; Moore et al.,
2008; Moore et al., 2009; Rong et al., 2009). Our results indicate the V1-V2 and C3 regions
remain immunodominant and the focus of the nAb response resulting in broadly cross-
neutralizing antibodies even during chronic progressive HIV-1 disease.
A decline of p24 antibody titers as disease progresses has previously been reported (Allain
et al., 1987; Binley et al., 1997; Forster et al., 1987; Lange et al., 1986), and it is therefore
not surprising that the p24-specific IgGs may lose their affinity over time. Chargelegue and
colleagues found that low p24 IgG affinity correlated with HIV-1 disease progression
(Chargelegue et al., 1995). Low affinity IgG HIV-1 specific binding antibodies may be
indicative of chronic disease progression. It is plausible that a relative decrease in the
binding affinity for activating FcγRIIa and FcγRIIIa may be consequent to changes in the
Fc portion of the IgGs which do not affect FcγRI binding. Polymorphisms in the FcγRIIa
(Forthal and Moog, 2009), and the extent of glycosylation of the antibodies (Forthal et al.,
2010) affect binding affinity. Additionally, a decrease in binding affinity of FcγRIIa was
associated with dysfunction in the expression of these receptors on the cells of the innate
immune system (Dugast et al., 2011). Dugast and colleagues purport that HIV infection is
associated with a number of changes in FcR expression on phagocytic cells that are
associated with changes in their ability to respond to antibody-opsonized targets, leading to
a failure in viral clearance in chronic infection (Dugast et al., 2011). We found a consistently
high affinity binding of IgG to FcγRI over time which may suggest that the non-neutralizing
pathway augmenting effector cell activity may be maintained during the chronic infection
stage. However, in the absence of a functional assay, our data do not provide definitive
answers on whether high affinity binding IgG to FcγRI is biologically significant in chronic
infection and what the profiles of the various FcγR-IgG binding were during the initial
HIV-1 infection stages.
Some limitations of our study are worth noting. Firstly, we only tested a limited number of
viral clones from each patient, and therefore may have biased the results of the study to the
cloned variants only. Secondly, we do not know the exact time of infection for the study
participants and relied on short-term median (21 months) follow-up immunological data,
which may be an unrepresentative snap-shot of the entire natural history of disease
progression for these participants. Thirdly, the small sample size meant that our study was
underpowered to reach definitive conclusions regarding the significance of breadth of
neutralization and autologous responses in attenuating disease. Fourthly, we used binding
affinity assays as an indication of the strength of affinity of the Fc portion of IgG to the
FcγRs which may affect downstream in vivo effector cell activity. Lastly, the dynamic
nature of IgG binding affinity to various FcγRs and the selective high affinity binding to
HIV-1 gp41 may be indicative of differences and evolution of the antibody mediated innate
antiviral immune response in progressive HIV-1 subtype C infection, although this will
require additional functional assays to prove.
Despite these caveats, the findings suggest that an ongoing de novo nAb response does not
directly protect against disease progression during chronic HIV-1 subtype C infection,
corroborating data from previous studies. Our results are also consistent with data from non-
human primate studies showing that high titer neutralizing antibody titers are not found in
sooty mangabeys (Li et al., 2010) suggesting that autologous nAb are not part of the
protection against disease progression in HIV and SIV infections. Furthermore, overall nAb
breadth increased over time in most subjects, regardless of their disease status. The
mechanism by which nAb breadth increased in these subjects is of interest. Thus, it will be
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important to determine which Env epitopes in chronically infected individuals elicit broadly
neutralizing antibodies and whether these provide any clinical benefit to the patient. In
addition, animal studies suggest that anti-HIV antibodies can protect against HIV-1 infection
(Burton et al., 2011; Hessell et al., 2009; Hessell et al., 2010) and vaccine-induced V1-V2
binding antibodies may be able to prevent infection (Haynes et al., 2012). Future studies will
need to address whether neutralizing and binding antibodies from HIV infected individuals
may be used to halt or reduce HIV acquisition.
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(A). Schematic illustrating the autologous neutralizing antibody challenge assays in all
participants over a median of 21 months from study entry to study exit. The average nAb
IC50 titers for study entry and exit Envs used in the assays are shown. The study entry Envs
were tested against nAbs from the study entry (contemporaneous) and study exit plasma
samples. Likewise the study exit Envs were tested against nAbs from the study entry and
study exit (contemporaneous) plasma samples. Figure 1(B) depicts the autologous nAb IC50
titers in study participant entry and exit plasma samples for all participants. Figure 1(C) and
1(D) shows the CD4 T-cell decline rate and the log viral load changes over time
respectively. P-values <0.05 were considered significant. P value was calculated using the
two-tailed Mann-Whitney non-parametric test overall. All the p values (p<0.0125) remained
statistically significant after Bonferroni adjustment for multiple comparisons.
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Correlation between the amino acid length of (A) V1-V5, (B) V1-V2 and (C) C2-V5 of Env
and autologous neutralization titers (nAb IC50 titer) when study entry viruses were tested
against study exit plasma samples. The Spearman r-coefficient and p-values are shown and a
correlation was considered significant when p<0.05.
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Heterologous responses of participant plasma tested at study entry and study exit against 20
Env pseudoviruses from a standard reference panel including subtypes C, B and A of tier
1A, 1B, tier 2 and 3 categories over a median of 21 months. The neutralization titer is shown
as reciprocal plasma dilution required to inhibit 50% of virus infectivity when the virus is
challenged with the participant's plasma. The highest titer (>1,000) is shown in red, and the
lowest in light orange, yellow depicts a titer of <1:45 that is below detection as shown
above.
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(A). IgG EC50 binding titers for gp41, gp120 and p24-specific antibodies at study entry and
exit time points. Panels for Figure 4(B) and (C) show the correlation of EC50 binding titers
for gp41, gp120 and p24-specific antibodies with CD4-T cell counts at study entry and study
exit respectively. None of the correlations were statistically significant (p< 0.05).
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(A). EC50 binding titers of IgGs for FcγRI, FcγRIIa, FcγRIIb and FcγRIIIa at study entry
and exit time points. Intra- or inter-group comparisons were statistically different i.e. p<
0.05. Figure 5(B) and (C). Correlation of CD4 T-cell counts at study entry and study exit
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with FcγRI, FcγRIIa, FcγRIIb and FcγRIIIa (EC50) are shown. Only p-values <0.05 are
shown.
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Table 2
HIV-1 Env pseudovirus panel of subtype C, B and A reference strains
HIV Isolate Viral Subtype Tiered Category Reference
MW965.25 C 1A NIH ARRRP#
ZM197 M.PB7 C 1B (Li et al., 2006)
ConC C 2 (Kothe et al., 2006)
DU156.12 C 2 (Li et al., 2006)
DU172.17 C 2 (Li et al., 2006)
ZM214 M.PL15 C 2 (Li et al., 2006)
CAP45.G3 C 2 (Li et al., 2006)
CAP239.G3 C 2 (Gray et al., 2007)
SF162.LS B 1A (Stamatatos and Cheng-Mayer, 1998)
6535.3 B 1B (Li et al., 2005)
AC10.0.29 B 2 (Li et al., 2005)
WITO 4160.33 B 2 (Li et al., 2005)
TRO.11 B 2 (Li et al., 2005)
QH0692.42 B 2 (Li et al., 2005)
PVO.4 B 3 (Li et al., 2005)
Q23ENV17 A 2 (Blish et al., 2007)
Q842ENVd12 A 2 (Blish et al., 2007)
Q168ENVa2 A 2 (Blish et al., 2007)
Q461ENVe2 A 2 (Blish et al., 2007)
Q769ENVd22 A 2 (Blish et al., 2007)
NIH ARRRP# - National Institutes of Health AIDS Research and Reference Reagent Program
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